Credit Suisse Ag Esperion Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 18,517 shares of ESPR stock, worth $34,441. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,517

Previous 19,272 3.92%

Holding current value

$34,441

Previous $57,000 14.04%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.02 - $3.02 $1,525 - $2,280	-755 Reduced 3.92%	18,517 $49,000
Q4 2023 Feb 08, 2024	BUY	$0.73 - $3.08 $1,127 - $4,755	1,544 Added 8.71%	19,272 $57,000
Q3 2023 Nov 13, 2023	SELL	$0.96 - $1.79 $2,475 - $4,616	-2,579 Reduced 12.7%	17,728 $17,000
Q2 2023 Aug 11, 2023	SELL	$1.2 - $1.76 $55,550 - $81,473	-46,292 Reduced 69.51%	20,307 $28,000
Q1 2023 May 10, 2023	BUY	$1.46 - $7.3 $6,813 - $34,069	4,667 Added 7.54%	66,599 $105,000
Q4 2022 Feb 13, 2023	BUY	$5.09 - $8.5 $233,167 - $389,376	45,809 Added 284.12%	61,932 $385,000
Q3 2022 Nov 10, 2022	SELL	$5.45 - $8.13 $172,579 - $257,444	-31,666 Reduced 66.26%	16,123 $108,000
Q2 2022 Aug 12, 2022	BUY	$4.77 - $6.67 $138,778 - $194,056	29,094 Added 155.62%	47,789 $304,000
Q1 2022 May 16, 2022	SELL	$3.34 - $5.56 $614,800 - $1.02 Million	-184,072 Reduced 90.78%	18,695 $86,000
Q4 2021 Feb 14, 2022	SELL	$4.81 - $11.92 $270,807 - $671,107	-56,301 Reduced 21.73%	202,767 $1.01 Million
Q3 2021 Nov 12, 2021	BUY	$11.34 - $21.37 $1.81 Million - $3.4 Million	159,308 Added 159.69%	259,068 $3.12 Million
Q2 2021 Aug 16, 2021	SELL	$19.4 - $28.71 $317,636 - $470,068	-16,373 Reduced 14.1%	99,760 $2.11 Million
Q1 2021 May 14, 2021	BUY	$25.12 - $36.89 $846,091 - $1.24 Million	33,682 Added 40.85%	116,133 $3.26 Million
Q4 2020 Feb 12, 2021	SELL	$24.2 - $35.76 $22.1 Million - $32.6 Million	-912,963 Reduced 91.72%	82,451 $2.14 Million
Q3 2020 Nov 13, 2020	BUY	$31.18 - $52.71 $4.35 Million - $7.36 Million	139,576 Added 16.31%	995,414 $37 Million
Q2 2020 Aug 12, 2020	SELL	$30.04 - $51.31 $1.08 Million - $1.84 Million	-35,868 Reduced 4.02%	855,838 $43.9 Million
Q1 2020 May 13, 2020	BUY	$27.44 - $73.84 $108,799 - $292,775	3,965 Added 0.45%	891,706 $28.1 Million
Q4 2019 Feb 12, 2020	SELL	$35.4 - $59.82 $2.3 Million - $3.88 Million	-64,915 Reduced 6.81%	887,741 $52.9 Million
Q3 2019 Nov 12, 2019	SELL	$34.47 - $47.53 $3.75 Million - $5.17 Million	-108,684 Reduced 10.24%	952,656 $34.9 Million
Q2 2019 Aug 14, 2019	SELL	$40.1 - $52.33 $3.53 Million - $4.61 Million	-88,075 Reduced 7.66%	1,061,340 $49.4 Million
Q1 2019 May 14, 2019	BUY	$40.11 - $53.57 $7.13 Million - $9.52 Million	177,780 Added 18.3%	1,149,415 $46.1 Million
Q4 2018 Feb 13, 2019	BUY	$36.99 - $59.11 $40,282 - $64,370	1,089 Added 0.11%	971,635 $44.7 Million
Q3 2018 Nov 13, 2018	SELL	$40.74 - $51.41 $5.01 Million - $6.33 Million	-123,053 Reduced 11.25%	970,546 $43.1 Million
Q2 2018 Aug 14, 2018	BUY	$36.2 - $76.4 $317,799 - $670,715	8,779 Added 0.81%	1,093,599 $42.9 Million
Q1 2018 May 15, 2018	BUY	$65.94 - $80.76 $4.53 Million - $5.55 Million	68,714 Added 6.76%	1,084,820 $78.5 Million
Q4 2017 Feb 14, 2018	SELL	$43.47 - $67.43 $2.08 Million - $3.23 Million	-47,932 Reduced 4.5%	1,016,106 $66.9 Million
Q3 2017 Nov 14, 2017	SELL	$43.8 - $52.77 $2.18 Million - $2.63 Million	-49,757 Reduced 4.47%	1,064,038 $53.3 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,113,795	1,113,795 $51.5 Million

Others Institutions Holding ESPR

# of Institutions

217

Shares Held

127M

Call Options Held

1.61M

Put Options Held

1.1M

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $124M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account